Mining the full potential of GPCR signaling to innovate novel drugs


Protein-NMR Conformation Driven Drug Discovery


Our proprietary membrane protein-NMR drug discovery platform identifies molecules that bind to G-protein coupled receptor (GPCR) targets, eliminating on-target adverse effects that limit therapeutic index.


We know the value of innovative drug discovery and development…

MEBIAS’ business model is comprised of advancing and partnering Mebias’ wholly owned molecules into early clinical development. The company has identified an  Investigational New Drug targeting the mu-opioid receptor in Phase 1 Clinical Studies. We are also developing Sphingosine 1-phosphate receptor agonists with the aim of treating neuropathic pain and neuroinflammation.


MEB-1170 is in Phase 1 human clinical trials



3675 Market Street Suite 200

Philadelphia, PA 19104